Opus Genetics COO Joseph Schachle Executes Automatic Sale of 4,644 Shares to Cover Tax Withholding

Automatic Share Sale Initiated by Restricted Stock Unit Vesting

Joseph K. Schachle, Chief Operating Officer of Opus Genetics, Inc., executed the sale of 4,644 common stock shares on July 23, 2026, at $2.94 per share, according to the company’s disclosure filing. This transaction was automatic and mandated by the company to satisfy tax withholding obligations triggered by the vesting and settlement of a restricted stock units (RSU) award, rather than a voluntary sale by Schachle.

Such automatic sales are common in corporate equity compensation plans, where companies manage tax liabilities by selling a portion of newly vested shares on behalf of executives. This predetermined sale differentiates it from discretionary market trades and reflects a procedural adjustment to Schachle’s equity holdings rather than a change in his investment stance.

Schachle’s Retained Equity Stake Post-Transaction

Following the July 23 sale, Schachle’s direct beneficial ownership stands at 291,440 shares of Opus Genetics common stock. This direct ownership implies full control and beneficial interest without intermediaries. Despite the automatic sale, Schachle’s significant equity position underscores his ongoing commitment to the company.

The filing does not disclose the total RSUs vested, the original award size, or the tax withholding amount necessitating the share sale. For further insight into Schachle’s equity compensation, investors should consult additional company disclosures such as proxy statements or annual reports containing executive compensation details.

Corporate Leadership and Tax Compliance Practices at Opus Genetics

This automatic sale highlights standard corporate procedures for handling tax obligations on executive equity awards. When RSUs vest, executives incur tax liabilities based on the fair market value of the shares. Companies often implement automatic "sell-to-cover" transactions to fulfill these obligations, avoiding the need for executives to provide separate funds.

This approach ensures timely tax payment compliance and reduces risks related to insider trading restrictions and securities regulations. By executing the sale at a set price on the vesting date, companies maintain orderly administration of equity compensation. Disclosures of such transactions provide transparency to investors, clarifying that these sales are routine tax-driven events rather than voluntary stock disposals.

Transaction Pricing and Market Context

The 4,644 shares were sold at $2.94 each, generating gross proceeds of approximately $13,653 before fees. Public information does not clarify any immediate impact on the stock price or market conditions surrounding the transaction date. The filing only specifies the transaction price without commentary on trading volume or stock performance on July 23, 2026.

Investors should note that the sale price corresponds to the automatic tax withholding sale and may differ from open-market prices. The RSUs vested were valued at Opus Genetics’ stock price on the settlement date, which determined both Schachle’s tax liability and the number of shares sold to cover withholding.

Regulatory Filing and Disclosure Obligations

The transaction was reported via a Form 4 filing with the Securities and Exchange Commission (SEC), required for officers, directors, and ten-percent beneficial owners upon changes in company securities holdings. As COO, Schachle is subject to Section 16 reporting rules. The filing was submitted on July 27, 2026, four days after the sale, in compliance with SEC prompt disclosure requirements.

The Form 4 includes detailed transaction data such as the security type, transaction code "S" for sale, number of shares, price, and beneficial ownership after the sale. An explanatory note clarifies the automatic nature of the sale to meet tax withholding obligations, distinguishing it from discretionary insider trades. This transparency assists investors in evaluating insider transactions accurately.

Schachle’s Role and Operational Leadership at Opus Genetics

Joseph K. Schachle serves as Chief Operating Officer of Opus Genetics, Inc., a NASDAQ-listed company headquartered at 8 Davis Drive, Suite 220, Durham, North Carolina. His role involves overseeing daily operations, supply chain management, technology infrastructure, and other functions supporting the company’s core business.

The filing does not provide additional details about Schachle’s tenure, responsibilities, or compensation. Investors seeking comprehensive background information should refer to proxy statements or other disclosures offering executive biographies and organizational structure.

Tax Withholding and Equity Compensation Mechanisms

Tax withholding is an integral aspect of RSU programs and equity compensation plans. Upon vesting, recipients incur income tax on the value of shares at that time, requiring withholding before share delivery. Companies commonly use automatic "sell-to-cover" arrangements to fulfill these obligations, selling enough shares to cover tax liabilities without requiring executives to pay out-of-pocket.

Opus Genetics’ filing confirms that Schachle’s July 23, 2026 share sale was mandated specifically to satisfy withholding taxes from RSU vesting, reflecting standard industry practice.

Insider Transaction Transparency and Investor Insights

Form 4 filings provide crucial transparency on insider transactions, enabling investors to monitor insider buying or selling patterns, distinguish mandatory sales from discretionary trades, and assess insider confidence. Heavy insider selling may signal concerns, but automatic tax withholding sales like Schachle’s are generally not interpreted as such.

Schachle’s automatic sale and subsequent retention of 291,440 shares indicate ongoing significant ownership and commitment. Investors should continue monitoring future Form 4 filings for any discretionary trades that might signal shifts in insider sentiment.

Power of Attorney and Filing Execution

The Form 4 was signed by Amy Rabourn on July 27, 2026, under power of attorney for Joseph K. Schachle. This delegation is common in corporate administration, allowing authorized individuals to handle regulatory filings without the executive’s personal signature on each document.

The delegated signature does not affect the disclosure’s accuracy or validity. The filing remains the official record of Schachle’s transaction and ownership, with all explanatory notes binding on the reporting person.